Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...

The clinical trial sector reflects on what it believes will be the biggest difficulties of 2025. Image credit: Shutterstock / 3rdtimeluckystudio It has been a turbulent time for the pharmaceutical ...

The never-ending challenge of finding and recruiting eligible clinical trial participants continues to push sponsors to find new avenues to expedite enrolment. As decentralisation shakes up ...

The trial will focus on subjects with difficult-to-treat rheumatoid arthritis. Credit: Chinnapong / Shutterstock. The European Medicines Agency (EMA) has approved Cullinan Therapeutics’ clinical trial ...

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...

Novartis announced the termination in its Q2 2025 earnings. Image credit: Melnikov Dmitriy / Shutterstock.com. Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after ...

Here are some trials for obesity medications to watch over the next 12 months. Image credit: Zdenek Macat / Getty Images The approval of Novo Nordisk’s Wegovy in 2021 catapulted the landscape of ...

China is an attractive study destination, yet our data-driven analysis shows the country’s clinical trial industry is still insular. Clinical Trials Arena maps the barricades. China’s increasing ...